ATE486892T1 - Verfahren zur kontrolle von krebs - Google Patents
Verfahren zur kontrolle von krebsInfo
- Publication number
- ATE486892T1 ATE486892T1 AT03794710T AT03794710T ATE486892T1 AT E486892 T1 ATE486892 T1 AT E486892T1 AT 03794710 T AT03794710 T AT 03794710T AT 03794710 T AT03794710 T AT 03794710T AT E486892 T1 ATE486892 T1 AT E486892T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- provides methods
- ephb4
- controlling cancer
- cancerous growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002951409A AU2002951409A0 (en) | 2002-09-16 | 2002-09-16 | Methods for regulating cancer |
| PCT/AU2003/001209 WO2004024773A1 (en) | 2002-09-16 | 2003-09-16 | Methods for regulating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486892T1 true ATE486892T1 (de) | 2010-11-15 |
Family
ID=27792678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03794710T ATE486892T1 (de) | 2002-09-16 | 2003-09-16 | Verfahren zur kontrolle von krebs |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7722866B2 (de) |
| EP (1) | EP1546205B1 (de) |
| JP (1) | JP4799863B2 (de) |
| KR (1) | KR20050072744A (de) |
| CN (1) | CN1694902B (de) |
| AT (1) | ATE486892T1 (de) |
| AU (1) | AU2002951409A0 (de) |
| BR (1) | BR0314369A (de) |
| CA (1) | CA2499130A1 (de) |
| DE (1) | DE60334820D1 (de) |
| ES (1) | ES2355503T3 (de) |
| MX (1) | MXPA05002894A (de) |
| NZ (1) | NZ539203A (de) |
| WO (1) | WO2004024773A1 (de) |
| ZA (1) | ZA200502863B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| EP1605961A4 (de) | 2003-03-12 | 2009-11-11 | Vasgene Therapeutics Inc | Polypeptid-verbindungen zur hemmung der angiogenese und des tumorwachstums |
| WO2005090406A2 (en) * | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| KR20120123619A (ko) | 2004-03-12 | 2012-11-08 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
| AU2005286663A1 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| CN101395183B (zh) * | 2006-01-05 | 2013-08-07 | 健泰科生物技术公司 | 抗ephb4抗体及其使用方法 |
| TWI391402B (zh) * | 2006-01-05 | 2013-04-01 | Genentech Inc | 抗ephb4抗體及使用該抗體之方法 |
| US8101365B2 (en) | 2006-01-05 | 2012-01-24 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
| AU2013200383B2 (en) * | 2006-01-05 | 2016-05-12 | Genentech,Inc. | Anti-EphB4 antibodies and methods using same |
| JP2010501596A (ja) * | 2006-08-31 | 2010-01-21 | エー・シー・エヌ・135 493 391・プロプライエタリー・リミテッド・アズ・トラスティー・フォー・コンカ・ユニット・トラスト | 抗体含有組成物を用いた非感染性の病状の処置および/または予防 |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| EP2137216A2 (de) * | 2007-03-12 | 2009-12-30 | Vasgene Therapeutics, Inc. | Verwendung von ephb4 als diagnostischer marker und therapeutisches ziel für eierstockkrebs |
| WO2008156642A1 (en) * | 2007-06-15 | 2008-12-24 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
| CN102083861B (zh) * | 2007-08-13 | 2016-04-13 | 瓦斯基因治疗公司 | 使用结合EphB4的人源化抗体的癌症治疗 |
| AU2015204311B2 (en) * | 2007-11-29 | 2017-06-08 | Molecular Health Gmbh | Novel tissue protective erythropoietin receptor (NEPOR) and methods of use |
| US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| ATE554186T1 (de) * | 2007-11-29 | 2012-05-15 | Molecular Health Gmbh | Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| WO2002026827A1 (en) | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
| EP1409549A4 (de) | 2001-06-20 | 2007-10-24 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren |
| EP1605961A4 (de) * | 2003-03-12 | 2009-11-11 | Vasgene Therapeutics Inc | Polypeptid-verbindungen zur hemmung der angiogenese und des tumorwachstums |
-
2002
- 2002-09-16 AU AU2002951409A patent/AU2002951409A0/en not_active Abandoned
-
2003
- 2003-09-16 ES ES03794710T patent/ES2355503T3/es not_active Expired - Lifetime
- 2003-09-16 AT AT03794710T patent/ATE486892T1/de not_active IP Right Cessation
- 2003-09-16 CN CN038251671A patent/CN1694902B/zh not_active Expired - Fee Related
- 2003-09-16 BR BR0314369-4A patent/BR0314369A/pt active Search and Examination
- 2003-09-16 KR KR1020057004541A patent/KR20050072744A/ko not_active Ceased
- 2003-09-16 EP EP03794710A patent/EP1546205B1/de not_active Expired - Lifetime
- 2003-09-16 DE DE60334820T patent/DE60334820D1/de not_active Expired - Lifetime
- 2003-09-16 CA CA002499130A patent/CA2499130A1/en not_active Abandoned
- 2003-09-16 MX MXPA05002894A patent/MXPA05002894A/es unknown
- 2003-09-16 US US10/528,029 patent/US7722866B2/en not_active Expired - Fee Related
- 2003-09-16 WO PCT/AU2003/001209 patent/WO2004024773A1/en not_active Ceased
- 2003-09-16 JP JP2004534869A patent/JP4799863B2/ja not_active Expired - Fee Related
- 2003-09-16 NZ NZ539203A patent/NZ539203A/en not_active IP Right Cessation
-
2005
- 2005-04-08 ZA ZA200502863A patent/ZA200502863B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004024773A1 (en) | 2004-03-25 |
| ZA200502863B (en) | 2006-06-28 |
| ES2355503T3 (es) | 2011-03-28 |
| EP1546205B1 (de) | 2010-11-03 |
| BR0314369A (pt) | 2005-08-09 |
| CN1694902B (zh) | 2012-10-10 |
| MXPA05002894A (es) | 2005-10-05 |
| EP1546205A1 (de) | 2005-06-29 |
| US20060134118A1 (en) | 2006-06-22 |
| US7722866B2 (en) | 2010-05-25 |
| AU2002951409A0 (en) | 2002-09-26 |
| KR20050072744A (ko) | 2005-07-12 |
| CN1694902A (zh) | 2005-11-09 |
| JP4799863B2 (ja) | 2011-10-26 |
| NZ539203A (en) | 2008-05-30 |
| CA2499130A1 (en) | 2004-03-25 |
| DE60334820D1 (de) | 2010-12-16 |
| JP2006517906A (ja) | 2006-08-03 |
| EP1546205A4 (de) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60334820D1 (de) | Verfahren zur kontrolle von krebs | |
| NO2017040I2 (no) | Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC | |
| ATE473754T1 (de) | Verfahren zur manipulation der zelldifferenzierung | |
| ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| ATE509955T1 (de) | Humanisierte kollagen-antikörper und damit verbundene verfahren | |
| UA87804C2 (ru) | Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir) | |
| CO5580797A2 (es) | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos | |
| EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
| DE602005017781D1 (de) | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| DK1325033T3 (da) | Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning | |
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| DE602004023965D1 (de) | Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| DK0724456T3 (da) | CD40-Antistoffer | |
| ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
| DE3687884D1 (de) | Monoklonale antikoerper und verfahren zum nachweis von pilzpathogenen. | |
| ATE476989T1 (de) | Humanisierter monoklonaler antikörper gegen von- willebrand faktor | |
| EP1411962A4 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
| DE60223688D1 (de) | Verfahren zur behandlung von multiplem myelom | |
| DE602004030041D1 (de) | Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen | |
| DE69615843D1 (de) | Il-8 antagonisten zur behandlung von asthma | |
| ATE285418T1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
| DE602006021324D1 (de) | Verfahren zur herstellung stabiler b-lymphozyten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |